How does 8NN's PB Ratio compare to its peers?

8NN is good value based on its Price-To-Book Ratio (3.8x) compared to the peer average (12.3x).

How does 8NN's PB Ratio compare vs other companies in the DE Biotechs Industry?

8NN is expensive based on its Price-To-Book Ratio (3.8x) compared to the European Biotechs industry average (2.4x).

What is 8NN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 8NN's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 8NN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 8NN's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Thor Medical (DB:8NN) - Stock Price, News & Analysis

8NN Stock Overview

Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details

8NN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue (NOK0)

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

Less than 3 years of financial data is available

+ 1 more risk

Thor Medical ASA Competitors

Heidelberg Pharma

XTRA:HPHA

€102.1m

2invest

XTRA:2INV

€62.7m

4SC

DB:VSC

€48.2m

Medigene

XTRA:MDG1

€22.5m

Price History & Performance

Summary of all time highs, changes and price drops for Thor Medical
Historical stock prices
Current Share Price	NOK 0.37
52 Week High	NOK 0.37
52 Week Low	NOK 0.064
Beta	0
11 Month Change	240.87%
3 Month Change	355.05%
1 Year Change	262.25%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	118.90%

Recent updates

Shareholder Returns

	8NN	DE Biotechs	DE Market
7D	167.4%	-0.7%	0.2%
1Y	262.3%	-17.2%	8.5%

Return vs Industry: 8NN exceeded the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 8NN exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is 8NN's price volatile compared to industry and market?
8NN volatility
8NN Average Weekly Movement	32.2%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 8NN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8NN's weekly volatility has increased from 26% to 32% over the past year.

About the Company

Founded	Employees	CEO	Website
2009	5	Jasper Kurth	www.thormedical.no

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.

Thor Medical ASA Fundamentals Summary

How do Thor Medical's earnings and revenue compare to its market cap?
8NN fundamental statistics
Market cap	€85.41m
Earnings (TTM)	-€1.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-53.1x

P/E Ratio

Is 8NN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8NN income statement (TTM)
Revenue	NOK 0
Cost of Revenue	NOK 0
Gross Profit	NOK 0
Other Expenses	NOK 18.56m
Earnings	-NOK 18.56m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 26, 2025

Earnings per share (EPS)	-0.079
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 8NN perform over the long term?

See historical performance and comparison

Thor Medical DB:8NN Stock Report